The Role of Leptin in Systemic Lupus Erythematosus: Is It Still a Mystery?

Nicolé Villa 1, Omar Badla 2, Raman Goit 1, Samia E. Saddik 1, Sarah N. Dawood 3, Ahmad M. Rabhi 1, Ahmad Mohammed 1, Aishwarya Raman 1, Manish Uprety 1, Maria Jose Calero 4, Maria Resah B. Villanueva 5, Narges Joshaghani 6, Lubna Mohammed 1

1. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
2. General Surgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
3. Pediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
4. Gynecology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
5. Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
6. Psychiatry and Behavioral Sciences, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA

Corresponding author: Nicolé Villa, nicolecuenc@hotmail.com

Abstract

Systemic lupus erythematosus (SLE) is a chronic inflammatory connective tissue disease with varying clinical manifestations. Recent studies have proposed that leptin may be related to SLE development. This study aims to assess current information regarding the relationship between leptin and SLE. A systematic search was done using PubMed, Google Scholar, ScienceDirect, Epistemonikos, and Cochrane Library databases. Studies published in the English language in the last 10 years were selected based on predefined eligibility criteria. The quality of the studies was evaluated using the Newcastle-Ottawa Scale and the Assessment of Multiple Systematic Reviews 2 tool. A total of 12 studies were included in this systematic review. These included systematic reviews/meta-analyses, cross-sectional studies, and case-control studies. Based on the findings of this review, we conclude that leptin is significantly elevated in SLE patients; however, it does not seem to correlate with disease activity. The exact mechanism of leptin in the pathogenesis of the disease remains unknown and further research is needed regarding this aspect.

Keywords: systematic review, sle, systemic lupus erythematosus, leptin receptor, leptin

Introduction And Background

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with varying clinical manifestations. This inflammatory connective tissue disorder affects more females than males [1]. Although it can present at any age, women of childbearing age are at a higher risk [2]. In the United States, the overall incidence of SLE from 2002 to 2009 was estimated to be 5.1 per 100,000 person-years. This data indicated that in 2018 approximately 14,263 people were newly diagnosed with this disease. Concerning race, in both male and female groups, the incidence was the highest among African Americans [3]. The etiology and pathogenesis of SLE are not clearly understood, but it is believed that it can be the result of a complex interaction of several factors, such as hormones, genetic predisposition, immune dysfunction, environment, and ethnicity [4,5]. SLE is characterized by the breakdown of self-tolerance, which leads to the production of autoantibodies, the deposition of immune complexes in several organs, and the presence of high levels of proinflammatory cytokines in the serum [5,6]. In patients with lupus, there is an increase in mortality due to infection, malignancy, atherosclerosis, and renal disease, which emphasizes the importance of understanding this disorder [2].

The adipose tissue is an endocrine organ that secretes adipokines such as leptin, adiponectin, resistin, and visfatin. Leptin is known to have a similar function to inflammatory cytokines including interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha (TNF-α) [7]. This gives leptin a role that goes beyond its well-known function of appetite regulation, introducing it as an important player in the immune system. In human beings, leptin has been associated with chronic inflammatory conditions such as rheumatoid arthritis, SLE, and intestinal inflammatory disease, among other conditions. High levels of leptin are associated with a decrease in T-regulatory cells (Treg) and an increase in Th17 cells, a process seen in the development of SLE [7,8]. Polymorphisms in genes that encode for leptin receptors have also been studied, and there is evidence that certain alleles are associated with either a higher or lower risk of SLE in different ancestral groups [9]. In mouse models of lupus, it has been shown that leptin promotes spontaneous lupus and that its antagonism decreases disease manifestations and aids in immune regulation [10].

In recent years, several studies have described a relationship between leptin levels and SLE, but the results have varied widely [11]. In this systematic review, we aim to assess current literature on the topic to further
investigate this association. We hope to provide a better understanding of the available evidence and help determine its clinical significance.

**Review**

**Methods**

This systematic review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines [12].

**Search Strategy**

We thoroughly searched PubMed, Cochrane Library, Google Scholar, ScienceDirect, and Epistemonikos. We used appropriate keywords and Medical Subject Heading (MeSH) terms to identify all potentially relevant articles describing the relationship between leptin and SLE. The keywords used included leptin, leptin receptor, level, systemic lupus erythematosus, and SLE. We applied the Boolean method to combine the keywords and MeSH terms to synthesize a uniform search through the various databases. The last date of the search through all the databases was April 10th, 2022. The description of the terms used in each database can be seen in Table 1.

| Database       | Keywords                                                                 | Search strategy                                                                 | Filters                                         |
|----------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------|------------------------------------------------|
| PubMed         | Leptin, Leptin receptor, level, systemic lupus erythematosus, SLE          | Systemic Lupus Erythematosus OR SLE OR (“Lupus Erythematosus, Systemic/blood”[Majr] OR “Lupus Erythematosus, Systemic/genetics”[Majr] OR “Lupus Erythematosus, Systemic/immunology”[Majr] OR “Lupus Erythematosus, Systemic/metabolism”[Majr] OR “Lupus Erythematosus, Systemic/physiology”[Majr] OR “Lupus Erythematosus, Systemic/physiopathology”[Majr] ) AND Leptin OR (“Leptin/blood”[Majr] OR “Leptin/genetics”[Majr] OR “Leptin/immunology”[Majr] OR “Leptin/metabolism”[Majr] OR “Leptin/physiology”[Majr] ) AND Leptin receptor OR (“Receptors, Leptin/blood”[Majr] OR “Receptors, Leptin/chemistry”[Majr] OR “Receptors, Leptin/genetics”[Majr] OR “Receptors, Leptin/immunology”[Majr] OR “Receptors, Leptin/metabolism”[Majr]) | Last 10 years, free full text, English language, humans |
| ScienceDirect  | Leptin, systemic lupus erythematosus, SLE                                 | Leptin AND SLE OR Systemic Lupus Erythematosus                                 | 2012–2022 research articles, review articles   |
| Cochrane       | Leptin, level, systemic lupus erythematosus, SLE                          | SLE AND Leptin                                                                 | 2012–2022                                      |
| Epistemonikos  | Leptin, systemic lupus erythematosus, SLE                                 | SLE OR Systemic Lupus Erythematosus AND Leptin                                 | Last 10 years                                 |
| Google Scholar | Leptin, level, systemic lupus erythematosus                              | Systemic Lupus Erythematosus AND Leptin Levels                                 | 2012–2022                                      |

**TABLE 1: Terms used for the bibliographic search with their corresponding filters.**

SLE: systemic lupus erythematosus

**Eligibility Criteria**

We restricted our search to online records in the English language, available as free full texts, and issued in the last 10 years (April 2012 to April 2022). We only included studies conducted among human participants. We restricted our choice of studies to systematic reviews, meta-analyses, cohort studies, case-control studies, and cross-sectional studies that provided data regarding plasma/serum leptin levels. We excluded case reports, editorials, animal studies, and gray literature.
We assessed each study for the potential risk of bias. We evaluated case-control studies using the Newcastle-Ottawa Scale (NOS), and for cross-sectional studies, we used an adapted version of the NOS. Systematic reviews and meta-analyses were assessed using the Assessment of Multiple Systematic Reviews 2 (AMSTAR 2) tool. Two authors (Nicole Villa and Omar Badla) independently reviewed the quality of the studies, and a score of at least 70% for each assessment tool was accepted.

Results

We identified a total of 780 records using the various search strategies across the databases. Out of the 780 records, 493 originated from PubMed, 66 from Google Scholar, 213 from ScienceDirect, seven from Epistemonikos, and one from the Cochrane Library. No other resource was used. We thoroughly checked all our records, organized them in alphabetical order using endnote, and then manually excluded 21 duplicates. The remaining 759 records were thoroughly screened for relevance based on titles and abstracts, after which 730 records were excluded. Hence, 29 articles were sought for retrieval, and after checking free full texts, we further removed eight records. We assessed 21 reports for eligibility, of which eight articles did not fulfill the inclusion and exclusion criteria. There was one article that met the study’s criteria but was of low quality and was excluded. Therefore, we included 12 articles, which included systematic reviews/meta-analyses, cross-sectional studies, and case-control studies. The complete PRISMA flowchart of our review is shown in Figure 1.

Study Characteristics

The main characteristics of the studies included in this systematic review are shown chronologically in Table 2. All the included studies were journal articles, of which six were case-control studies, four were cross-sectional studies, and two were systematic reviews/meta-analyses.
| Author                        | Year | Region | Study Design | Case n | Sex ratio (F/M) | Control n | Sex ratio (F/M) | Criteria of the classification of SLE | Measurement of leptin |
|------------------------------|------|--------|--------------|--------|----------------|-----------|----------------|---------------------------------------|-----------------------|
| Liangliang et al. [13]       | 2015 | China  | Case-control | 87     | 76/11          | 85        | 71/14          | SLICC                                | ELISA                 |
| De Souza Barbosa et al. [14] | 2015 | Brazil | Case-control | 52     | 52/0           | 33        | 33/0           | ACR                                  | ELISA                 |
| Margiotta et al. [15]        | 2016 | Italy  | Case-control | 13     | 13/0           | 11        | 11/0           | SLICC                                | ELISA                 |
| Hong Miao et al. [16]        | 2017 | China  | Case-control | 633    | 573/60         | 559       | 553/6          | ACR                                  | ELISA                 |
| Wang et al. [17]             | 2017 | China  | Case-control | 47     | 47/0           | 25        | 25/0           | ACR                                  | ELISA                 |
| Mohammed et al. [18]         | 2017 | Egypt  | Case-control | 40     | 40/0           | 20        | 20/0           | ACR                                  | ELISA                 |
| Muhammad et al. [19]         | 2019 | Indonesia | Cross-sectional | 35    | 35/0           | 35        | 35/0           | Not reported                         | ELISA                 |
| Balaji et al. [20]           | 2020 | India  | Cross-sectional | 80    | N/A*          | 40        | N/A*           | SLICC                                | ELISA                 |
| Aghdashi et al. [21]         | 2020 | Iran   | Cross-sectional | 40    | 40/0           | 40        | 40/0           | ACR                                  | ELISA                 |
| Kondratyeva et al. [22]      | 2021 | Russia | Cross-sectional | 46    | 46/0           | N/A       | N/A            | ACR                                  | ELISA                 |

**TABLE 2: The main characteristics of case-control and cross-sectional studies included in the review.**

*: In the study by Balaji et al., the exact number of female and male participants was not mentioned but the article did report a male:female ratio of 1:12 in cases as well as in controls.

N/A: not applicable; F/M: female/male; SLE: systemic lupus erythematosus; SLICC: Systemic Lupus International Collaborating Clinics; ACR: American College of Rheumatology; ELISA: enzyme-linked immunosorbent assay

Because of the few systematic reviews and meta-analyses published in the field, we elected to include them in this review. The characteristics of these studies are shown in Table 3.
### Table 3: The main characteristics of the systematic review and meta-analysis included in the review.

| Author       | Year | Type of study                  | Databases reviewed                                                                 | Number of studies included | Total participants | Inclusion and exclusion criteria                                                                 | Outcomes and key points                                                                 | Funding                        |
|--------------|------|--------------------------------|-------------------------------------------------------------------------------------|----------------------------|-------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------|
| Lee et al.   | 2018 | Meta-analysis                  | Medline, Embase, Cochrane                                                          | 20                         | 1,333 patients and 1,048 controls | Inclusion criteria: case-control, cross-sectional, or cohort studies with data on serum/plasma leptin levels in case and control groups. No language and race restrictions. Exclusion criteria: overlapping or insufficient data, reviews, and case reports | Leptin levels were elevated in SLE patients regardless of ethnicity, data type, sample size, and matched variables. The study proposed that leptin may have an important role in the pathogenesis of SLE, but the exact mechanism is not clear. | No external funding |
| Yuan et al.  | 2020 | Systematic review and meta-analysis | PubMed, Embase, Cochrane, China National Knowledge Infrastructure, China WanFang, China Weipu | 34                         | 1,744 patients and 1,411 controls | Inclusion criteria: cohort, case-control, and cross-sectional studies with data on the serum/plasma leptin levels, leptin receptor levels, and relevant gene polymorphism in case and control groups, studies with predefined SLE criteria and measurement methods, studies with OR estimates with 95% CI and p-values. Exclusion criteria: case reports, editorials, letters, comments, review articles, meta-analysis, and non-human subjects | Leptin levels were higher in SLE patients regardless of source, sample size, or assay method. In terms of ethnicity, leptin levels were elevated in Asian, African, North American, and European groups. SLE patients showed a decreased trend of leptin receptor levels. | Received external funding |

**Discussion**

In recent years, the relationship between SLE and leptin levels has received more attention, and several studies have been performed on this topic. However, the results vary widely making it challenging to draw solid conclusions from a single study. Due to the importance of SLE, in this systematic review, we analyzed recent literature to help elucidate the role of leptin in this autoimmune condition.

**The Possible Role of Leptin in the Pathogenesis of SLE**

It has been described that leptin plays a role in immunity, regulating both the innate and adaptative responses. In the adaptative response, leptin decreases the proliferation of TReg cells while it promotes the proliferation of naïve T and B cells. In the innate response, leptin increases the cytotoxicity of natural killer cells and enhances the chemotaxis of macrophages and monocytes. Leptin also increases the expression of B-cell lymphoma 2 (BCL-2) in T cells, delaying their apoptosis [23,24]. In mouse models, it was shown that leptin-deficient mice had a higher number and activity of TReg cells which provided them resistance to autoimmune diseases [25].

Leptin favors a switch toward Th1 inflammatory cytokines such as interferon-gamma, IL-6, and TNF-α. On the other hand, it downregulates the Th2 anti-inflammatory cytokines including IL-4 and IL-10. In doing so, leptin creates an imbalance between Th1 and Th2 lymphocytes, and at the same time, it facilitates Th17 differentiation. Leptin has been shown to modulate the development of B lymphocytes and activate them to secrete cytokines, worsening the inflammatory state. A deficit in TReg cell function and a notable Th17 differentiation are also observed in lupus [4,24]. Therefore, by the mechanisms described, leptin may be involved in the pathogenesis of lupus.

**Leptin Levels in Patients With SLE**
In all the case-control and cross-sectional studies included in this review, leptin was measured by enzyme-linked immunosorbent assay (ELISA). We found that most of the studies showed that SLE patients had higher leptin levels in plasma or serum in comparison to healthy controls. In a cross-sectional study that included only SLE patients, Kondratyeva et al. reported that 76% of the patients had hyperleptinemia [22]. In contrast to these findings, in a study performed on an Indonesian population, the SLE group had a higher mean leptin level, but the difference was not statistically significant [19]. Another study in which no difference was seen between the two groups was a case-control study performed on an Italian population by Margiotta et al. [15].

However, in the systematic review and meta-analysis included in this review, it was shown that leptin was significantly higher in SLE patients. Lee et al. reported in their meta-analysis that leptin levels were higher in patients with SLE independent of sex, body mass index, sample size, age, or data type [23]. Whereas the subgroup analysis by sex reported by Yuan et al. showed that leptin was significantly elevated in the female group with SLE but not in the male group [4]. This finding could be explained by the fact that in many of the studies that they included, the population was mainly female, which is understandable because lupus is much more prevalent in females [4,26].

Concerning the relationship between ethnicity and leptin levels in SLE patients, the study by Yuan et al. included Asian, North American, European, South American, and African participants, and the study by Lee et al. included Caucasian, Asian, Arab, Latin American, and mixed ethnic populations. Both studies showed that leptin was significantly higher in SLE patients belonging to the Asian and European groups [4,25].

Disease Activity and Leptin

The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) is a tool designed to help clinicians measure disease activity in patients with lupus. The index was developed by rheumatologists with expertise in SLE, and since its introduction, it has been widely used in clinical practice and in several studies [27]. This index takes into consideration clinical manifestations and laboratory values and aims to reflect the disease activity within the last 10 days. Based on the score, clinicians can determine if the patient has an active or inactive disease, the severity of the active disease, and whether there has been a flare-up [28].

Of the 12 studies included in the review, only 10 had information regarding the relationship between leptin levels and disease activity measured by SLEDAI. Out of these, only three studies showed a positive correlation between disease activity measured by SLEDAI and leptin level [17,21,22]. In 2020, Yuan et al. showed that even though there was a trend toward higher leptin levels in patients with a SLEDAI score above 10, this was not significant when compared to those with a score lower than 10 [4].

It is not clear whether leptin is related to specific clinical manifestations. Mohammed et al. showed that leptin was higher in patients who had alopecia and renal affection [18]. On the other hand, Balaji et al. described that leptin was higher in patients with malar or discoid rash, alopecia, and those with musculoskeletal manifestations [20]. However, this data was not significant, and to our knowledge, to date, there are not many studies that show that leptin is higher or lower with specific clinical manifestations.

LEP and Leptin Receptor Gene Polymorphisms in SLE

Recent studies have analyzed the association of leptin-related polymorphisms in patients with lupus to decipher its possible impact on susceptibility to the disease.

In 2016, Li et al. conducted a study in a Chinese population in which they investigated the LEP and leptin receptor (LEPR) gene single-nucleotide polymorphisms in patients with SLE and controls. They did not find an association between the different polymorphisms and the risk for SLE. However, in the LEP gene, they showed that lupus patients with pericarditis had higher frequencies of the TT genotype and T allele frequencies of the rs2071045 polymorphism. Concerning the LEPR, they found an association between the GA/GG genotype and G allele frequencies of the rs3806318 polymorphism and the presence of photosensitivity. As to the SLEDAI score, there was no difference in genotype distribution in patients with a score above 10 when compared to those with a score below this value [16].

Zhao et al. performed a large study with a total of 15,706 participants from different ancestral groups and reported similar results. The investigators found that in LEP the A allele of rs3828942 increased the risk of SLE in African Americans. Conversely, the A allele of rs12706832 was related to a decreased risk in the same population. LEPR rs1892535 and rs6690625 were associated with a diminished risk of lupus in a population Hispanic enriched for the Amerindian European admixture. However, a consistent association between the different polymorphisms in multiple ancestral groups was not found. Therefore, the leptin-related polymorphisms analyzed were not associated with a higher susceptibility to developing lupus [29].

Body Mass Index and Leptin

Zhao et al. performed a large study with a total of 15,706 participants from different ancestral groups and reported similar results. The investigators found that in LEP the A allele of rs3828942 increased the risk of SLE in African Americans. Conversely, the A allele of rs12706832 was related to a decreased risk in the same population. LEPR rs1892535 and rs6690625 were associated with a diminished risk of lupus in a population Hispanic enriched for the Amerindian European admixture. However, a consistent association between the different polymorphisms in multiple ancestral groups was not found. Therefore, the leptin-related polymorphisms analyzed were not associated with a higher susceptibility to developing lupus [29].
Because leptin is related to adipose tissue, body mass index (BMI) is a factor that should be taken into consideration due to the effect it can have on leptin levels. Paul et al. described that in healthy subjects, serum leptin concentration progressively augmented with an increase in BMI [30]. This association was also reported by Martins et al.; in their study, BMI was not only strongly associated with leptin but was also considered a great predictor of hyperleptinemia on receiver operating characteristic (ROC) analysis [31].

Mohammed et al. reported similar findings; in their study, the mean BMI in SLE patients was 25.36 kg/m², and it had a positive correlation with leptin levels. They also described an association between leptin and total cholesterol values [18]. Barbosa et al. reported that SLE subjects had a higher BMI in comparison to healthy controls, and BMI had a positive correlation with leptin levels only in lupus patients. However, in their study, leptin was associated with high-density lipoprotein (HDL) cholesterol and not with total cholesterol [14]. These findings go hand in hand with those of Balaji et al. who also reported that leptin was correlated with BMI and HDL cholesterol [20]. In our systematic review, each study had different inclusion and exclusion criteria; in some cases, just accepting patients within a specific BMI range which could be related to their findings on leptin levels.

Limitations
This study has some limitations that should be considered. First, this review only considered studies that were published in the last 10 years, published in the English language, and that were available as full text. Second, most of the studies included had small sample sizes, and the patients had different clinical features, demographic characteristics, and received different treatments. The variables controlled differed widely making it challenging to compare the data reported by different studies. Nevertheless, our study also has its strengths. In comparison with a single study, in this systematic review, we were able to provide more knowledge about the existing relationship between leptin and SLE. We consider that the information provided in this review can guide future studies on this topic.

Conclusions
Leptin is significantly elevated in SLE patients, but the exact mechanism of how it is related to the pathogenesis of the disease remains unclear. Based on the findings of this review, leptin levels do not appear to correlate with disease activity in lupus patients. The distinct gene polymorphisms of LEP and LEPR could be related to certain clinical manifestations, but they do not appear to increase the risk for the development of SLE. Due to the association between BMI and leptin levels, BMI is a variable that should be taken into consideration when evaluating leptin in SLE patients. Most of the studies on this topic were performed on a small number of patients and had very different inclusion and exclusion criteria, which could explain the controversial results obtained. Further research is needed to explore the connection between leptin and lupus, to clarify its role in the development of the disease, and whether it can be used as a tool to aid early diagnosis. For future investigations on the topic, we suggest conducting a study with a larger sample of patients, and when examining leptin levels in SLE patients, taking into consideration variables such as sex, ethnicity, treatment received, and BMI.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Zucchi D, Elefante F, Schirolli D, Signorini V, Trentin F, Bortoluzzi A, Tani C: One year in review 2022: systemic lupus erythematosus. Clin Exp Rheumatol. 2022, 40:4-14. 10.5563/clinexpheumatol/n0sy
2. Feltz M, Wickham MB: Systemic lupus erythematosus: the devastatingly deceptive disease . Clin Rev. 2016, 26:38-46.
3. Iznitry PM, Fenerci ED, Somers EC, et al.: Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. Lupus Sci Med. 2021, 8:e000614. 10.1136/lupus-2021-000614
4. Yuan Q, Zhang L, Tian Y, Li W, Li X, Lu Z: Circulating leptin level, soluble leptin receptor level and their gene polymorphism in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Clin Exp Rheumatol. 2020, 38:1238-46.
5. Paul HS, Lu MP, Wang JH, Xu M, Yang SR: Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020, 16:19-30. 10.1007/s12519-019-00229-3
6. Pan LM, Li XP, Leng RX, Li XM, Pan HF: Plasma/Seum leptin levels in patients with systemic lupus erythematosus: a meta-analysis. Arch Med Res. 2015, 46:551-6. 10.1016/j.arcmed.2015.09.005
7. Barbosa Vde S, Régo I, Antônio da Silva N: Possible role of adipokines in systemic lupus erythematosus and
rheumatoid arthritis. Rev Bras Reumatol. 2012, 52:278-87. 10.1590/0482-50042012000200011
8. Uzrall AH, Swellmeen L: Leptin and systemic lupus erythematosus: a comprehensive review. Trop J Pharm Res. 2020, 19:1529-37. 10.4314/tjpr.v19i6.30
9. La Cava A: Leptin-related polymorphisms and SLE. Inflamm Cell Signal. 2016, 4:e1171.
10. Lourenço EV, Liu A, Matarese G, La Cava A: Leptin promotes systemic lupus erythematosus by increasing autoantibody production and inhibiting immune regulation. Proc Natl Acad Sci U S A. 2016, 113:10657-42. 10.1073/pnas.1607101115
11. Misra D: Leptin and lupus. . . . . . . the story continues! Indian J Rheumatol. 2021, 16:1-2. 10.4103/ijnr.injr_47_21
12. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136/bmj.n71
13. Ma L, Li D, Sookha MR, et al.: Elevated serum leptin levels in patients with systemic lupus erythematosus. Pharmazie. 2015, 70:720-3. 10.1691/ph.2015.5649
14. Barbosa Vde S, Francescantónio PL, Silva NA: Leptin and adiponectin in patients with systemic lupus erythematosus: clinical and laboratory correlations. Rev Bras Reumatol. 2015, 55:140-5. 10.1016/j.rhr.2014.08.014
15. Margiotta D, Navarini L, Vadacca M, et al.: Relationship between leptin and regulatory T cells in systemic lupus erythematosus: preliminary results. Eur Rev Med Pharmacol Sci. 2016, 20:636-41.
16. Li HM, Zhang TP, Leng RX, et al.: Association of leptin and leptin receptor gene polymorphisms with systemic lupus erythematosus in a Chinese population. J Cell Mol Med. 2017, 21:373-42. 10.1111/jcm.m.13095
17. Wang X, Qiao Y, Yang L, et al.: Leptin levels in patients with systemic lupus erythematosus inversely correlate with regulatory T cell frequency. Lupus. 2017, 26:1401-6. 10.1177/0961203317703497
18. Mohammed SF, Abdalla MA, Junaaril WM, Sheta MM: Serum leptin in systemic lupus erythematosus patients: its correlation with disease activity and some disease parameters. Egypt Rheumatol. 2018, 40:23-7. 10.1016/j.iejr.2017.06.005
19. Reagan M, Salim NA, Junaidi, Hermansyah: Comparison of leptin serum levels between systemic lupus erythematosus (SLE) and non-SLE patients at Mohammad Hoesin Hospital Palembang. J Phys Conf Ser. 2019, 1246:012046. 10.1088/1742-6596/1246/1/012046
20. Balaji C, Saranya C, Bhuvenesh M, Ramesh R, Srima S, Rajeshwari S: Serum Adipokine leptin levels in systemic lupus erythematosus patients and its correlation with clinical manifestations and disease activity - a cross-sectional study from a tertiary care center. Indian J Rheumatol. 2021, 16:5-8. 10.4103/ijnr.injr_6_20
21. Aghdashi MA, Salami S, Hajian A: Evaluation of serum leptin level and its association with disease activity and some inflammatory factors in systemic lupus erythematosus. J Babol Univ Med Sci. 2020, 22:156-61. 10.22088/jbums.22.1.156
22. Kondratyeva I, Panafidina TA, Popkova T, Gurbasona YN, Cherkasova MV: [Clinical significance of leptin in systemic lupus erythematosus]. Sovremennaya Revmatologiya. 2021, 15:61-6. 10.14412/1996-7012-2021-6-61-66
23. Lee YH, Song GG: Association between circulating leptin levels and systemic lupus erythematosus: an updated meta-analysis. Lupus. 2018, 27:428-35. 10.1097/art.2018.00307
24. Francisco V, Pino J, Campos-Cabaleiro V, et al.: Obesity, fat mass and immune system: role for leptin. Front Physiol. 2018, 9:640. 10.3389/fphys.2018.00640
25. Matarese G, Procaccini C, De Rosa V, Horvath TL, La Cava A: Regulatory T cells in obesity: the leptin connection. Trends Mol Med. 2010, 16:247-56. 10.1016/j.molmed.2010.04.002
26. Yacoub Wasef SZ: Gender differences in systemic lupus erythematosus. Gend Med. 2004, 1:12-7. 10.14412/1996-8579(04)08006-8
27. Gladman DD, Ibáñez D, Urowitz MB: Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002, 29:288-91.
28. Yee CS, Farewell VT, Isenberg DA, et al.: The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2011, 50:982-8. 10.1093/rheumatology/keq76
29. Zhao J, Wu H, Langefeld CD, et al.: Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. Clin Immunol. 2015, 161:157-62. 10.1016/j.clim.2015.09.007
30. Paul RF, Hassan M, Nazar HS, Gillani S, Afzal N, Qayyum I: Effect of body mass index on serum leptin levels. J Ayub Med Coll Abbottabad. 2011, 29:40-5.
31. Martins Mdo C, Lima Faleiro I, Fonseca A: [Relationship between leptin and body mass and metabolic syndrome in an adult population]. Rev Port Cardiol. 2012, 31:71-9. 10.1016/j.repco.2012.08.002